Karbon-X Project Inc.
CALGARY, AB / ACCESSWIRE / March 6, 2024 / Karbon-X, an innovative carbon offset company known for its pioneering subscription service and custom offsetting solutions for businesses and organizations, proudly announces the appointment of Brett Hull and Justin Bourque to its Board of Directors, effective February 26, 2024. This strategic move marks a significant step forward in the company's mission to combat climate change through advanced carbon offsetting solutions accessible via an app and website.
Chad Clovis, CEO of Karbon-X, shared his enthusiasm about the new appointments: "I am delighted to announce the appointment of Brett Hull and Justin Bourque to our Board of Directors. Their extensive experience and expertise in their respective fields will be invaluable assets as we continue to navigate the challenges and opportunities ahead. Brett Hull is a legendary figure in the hockey world and his extensive experience will serve Karbon-X well. Likewise, we are thrilled to welcome Justin Bourque to our board, a recognized leader both inside and out of the indigenous community. As Karbon-X embarks on this new chapter, I am confident that Brett and Justin will play pivotal roles in driving our company forward. Their passion, dedication, and commitment to excellence align perfectly with our values and objectives."
Brett Hull, renowned for his illustrious career in ice hockey, brings a wealth of experience in sports management and team leadership to Karbon-X. Hull, a Canadian-American former professional ice hockey player, general manager, and currently an executive vice president of the St. Louis Blues, is celebrated for his scoring prowess and leadership on and off the ice. Hull's career, highlighted by 741 goals, ranks fifth highest in NHL history, and his achievements include two Stanley Cup victories and recognition as one of the 100 Greatest NHL Players in history.
Justin Bourque is an experienced leader with a profound commitment to fostering relationships between industry and Indigenous communities. As the Founder and President of Âsokan Generational Developments, Bourque has led several major projects and complex Indigenous equity ownership transactions, demonstrating a unique blend of innovation, leadership, and dedication to Indigenous sovereignty and economic resilience. His work has earned him prestigious accolades, including Queen Elizabeth II's Platinum Jubilee Medal and inclusion in the Indigenomics Institute 10 To Watch List, highlighting his contributions to the $100 billion Indigenous economy.
The addition of Hull and Bourque to the Karbon-X Board of Directors aligns with the company's vision to lead in the carbon offsetting sector by leveraging their unique insights, experiences, and leadership qualities. Their appointments are expected to propel Karbon-X towards new heights in environmental sustainability and corporate responsibility.
About Karbon-X
Karbon-X is at the forefront of the fight against climate change, offering a subscription service that allows individuals and organizations to sponsor projects that offset carbon footprints through an innovative app and website. Additionally, Karbon-X provides custom carbon offsetting solutions for businesses and organizations, aiming to make sustainability achievable for all. With a commitment to environmental stewardship and innovation, Karbon-X is dedicated to creating a greener, more sustainable future. Learn more at www.Karbon-X.com.
Contact Information:
Daniel Haigh
Head of Marketing
1 587 577 3863
dh@Karbon-X.com
SOURCE: Karbon-X
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom